Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
This preliminary analysis of a real-world study demonstrated the comparable effectiveness of ribociclib and palbociclib with AI as an initial therapy for HR + /HER2 - ABC. No statistically significant difference in PFS, OS, and TTC was found in patients treated with AI combined with palbociclib or ribociclib. Longer follow-up and further prospective randomized head-to-head studies are warranted.
Authors
- Napa Parinyanitikul (ORCID: https://orcid.org/0000-0003-3701-5663)
- Archara Supavavej (ORCID: https://orcid.org/0000-0002-3270-5553)
- Concord Wongkraisri (ORCID: https://orcid.org/0000-0002-8819-4211)
- Suthinee Ithimakin (ORCID: https://orcid.org/0000-0002-4205-6112)
- Thitiya Dejthevaporn (ORCID: https://orcid.org/0000-0003-1808-7303)
- Sunee Neesanun (ORCID: https://orcid.org/0000-0002-8349-3730)
- Arunee Dechaphunkul (ORCID: https://orcid.org/0000-0002-0593-4385)
- Patrapim Sunpaweravong (ORCID: https://orcid.org/0000-0001-9787-270X)
- Thanate Dajsakdipon (ORCID: https://orcid.org/0000-0002-3474-3414)
- Charuwan Akewanlop (ORCID: https://orcid.org/0000-0003-1022-3745)
- Thiti Susiriwatananont (ORCID: https://orcid.org/0000-0001-6916-3383)
Institutions
- Prince of Songkla University (TH)
- Siriraj Hospital (TH)
- Chulalongkorn University (TH)
- Mahidol University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Chulabhorn Hospital (TH)
- Ramathibodi Hospital (TH)
- Charoenkrung Pracharak Hospital (TH)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1186/s12885-024-12765-x
- Citations
- 8
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- Mahidol University
- Faculty of Medicine Siriraj Hospital, Mahidol University